MBF Theraupeutics

MBF Therapeutics is an immunotherapeutic animal health company focused on the use of its innovative T-Max™ DNA vaccine platform to create disruptive products for infectious disease and cancer.

Initial development is focused on highly efficacious, universal vaccines that prevent significant current and new infectious diseases in animals with translational opportunities in humans.
Learn More About the T-Max Platform

One World. One Health.

The concept of One World One Health has been widely discussed for a number of years, but the recent pandemics have highlighted the importance of the interrelationships between diseases in animals and humans. Many of these represent some of the most serious threats and increasingly require new and more innovative approaches to safely protect animals and humans. MBF Therapeutics is dedicated to using our innovative T-Max™ DNA vaccine platform to address these serious problems in animal health which should also create opportunities for establishing proof of concept clinical data that will allow development of specific opportunities in human health. MBFT will pursue these human health opportunities through separately funded subsidiaries while seeking partnerships with major vaccine companies.
Learn More About MBFT’s ESG

Pipeline

The Importance of T-cells

T cell vaccines are epidemiologically important for disease control and prevention because they reduce the severity of viremia, fever, and duration of illness in individuals and reduce viral shed and spread within herds, thus mitigating the spread, duration and economic losses that result from failure to contain highly infectious viruses (Price et al. 2014). Reducing viral spread slows the rate of emergence of viral variants that arise by antigenic shift and drift. Respiratory tract-resident effector T cells control innate dysregulation and cytokine storms that cause lung destruction and mortality (Li et al. 2008; Iwasaki et al. 2020). We create protective, multi-antigen T cell vaccines that prime the immune system against specific viral antigens to elicit rapid, potent cellular immune responses at the site of infection.